A Phase II, Multicenter Study to Investigate the Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma
Latest Information Update: 07 Jul 2022
At a glance
- Drugs SHC-014748M (Primary)
- Indications Anaplastic large cell lymphoma; Panniculitis; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Nanjing Sanhome Pharmaceutical
Most Recent Events
- 15 Jul 2020 New trial record